- Research article
- Open Access
- Open Peer Review
Simplifying the detection of MUTYH mutations by high resolution melting analysis
© López-Villar et al; licensee BioMed Central Ltd. 2010
- Received: 1 February 2010
- Accepted: 5 August 2010
- Published: 5 August 2010
MUTYH-associated polyposis (MAP) is a disorder caused by bi-allelic germline MUTYH mutation, characterized by multiple colorectal adenomas. In order to identify mutations in MUTYH gene we applied High Resolution Melting (HRM) genotyping. HRM analysis is extensively employed as a scanning method for the detection of heterozygous mutations. Therefore, we applied HRM to show effectiveness in detecting homozygous mutations for these clinically important and frequent patients.
In this study, we analyzed phenotype and genotype data from 82 patients, with multiple (>= 10) synchronous (19/82) or metachronous (63/82) adenomas and negative APC study (except one case). Analysis was performed by HRM-PCR and direct sequencing, in order to identify mutations in MUTYH exons 7, 12 and 13, where the most prevalent mutations are located. In monoallelic mutation carriers, we evaluated entire MUTYH gene in search of another possible alteration. HRM-PCR was performed with strict conditions in several rounds: the first one to discriminate the heteroduplex patterns and homoduplex patterns and the next ones, in order to refine and confirm parameters. The genotypes obtained were correlated to phenotypic features (number of adenomas (synchronous or metachronous), colorectal cancer (CRC) and family history).
MUTYH germline mutations were found in 15.8% (13/82) of patients. The hot spots, Y179C (exon 7) and G396D (exon 13), were readily identified and other mutations were also detected. Each mutation had a reproducible melting profile by HRM, both heterozygous mutations and homozygous mutations. In our study of 82 patients, biallelic mutation is associated with being a carrier of ≥10 synchronous polyps (p = 0.05) and there is no association between biallelic mutation and CRC (p = 0.39) nor family history (p = 0.63). G338H non-pathogenic polymorphism (exon 12) was found in 23.1% (19/82) of patients. In all cases there was concordance between HRM (first and subsequent rounds) and sequencing data.
Here, we describe a screening method, HRM, for the detection of both heterozygous and homozygous mutations in the gene encoding MUTYH in selected samples of patients with phenotype of MAP. We refine the capabilities of HRM-PCR and apply it to a gene not yet analyzed by this tool. As clinical decisions will increasingly rely on molecular medicine, the power of identifying germline mutations must be continuously evaluated and improved.
- Familial Adenomatous Polyposis
- High Resolution Melting
- High Resolution Melting Analysis
- Biallelic Mutation
- MUTYH Mutation
MAP is a disorder caused by bi-allelic germline MUTYH mutations, characterized by multiple colorectal adenomas. Mutations are distributed over the MUTYH locus, most of the changes found are missense mutations, of which Y179C and G396D, located in MUTYH exons 7 and 13 respectively, pose approximately 73% of mutations found in western populations [1, 2]. Analysis of 82 selected patients was performed by HRM-PCR and direct sequencing, in order to identify mutations in MUTYH exons 7, 12 and 13. We also analyzed the prevalence of a non-pathogenic polymorphism, located in exon 12: G338H . We evaluated the ability of HRM  for genotype at specific positions and also unknown mutations. HRM has become an alternative for screening for molecular diagnosis. In normal application HRM-PCR, discriminates heteroduplexes, which melt at lower temperatures than homoduplexes . However, mutant homozygotes have been reported on the germline MUTYH gene . The importance of identifying these mutations is based on the fact that MAP represents a syndrome predisposing colorectal cancer with an autosomal recessive pattern. In fact, these mutations are responsible for as many as 40% of cases with attenuated familial adenomatous polyposis without mutations in the APC gene. In this regard, downstream assays are limited in clinical decision-making and outcome [4–6]. Thus, this application provides a platform for detection of germline mutations in MUTYH gene. HRM-PCR was performed in several rounds with specific primers: the first one discriminating heteroduplex and homoduplex patterns and the next ones, in order to refine the tight conditions. Biallelic MUTYH mutations have also been found to be appended with 93-fold excess risk of colorectal cancer, with practically complete penetrance by 60 years of age .
Phenotypic features of 82 patients
Type of Adenomas
Patients with multiple ≥ 10) polyps synchronous
Patients with multiple (≥ 10) polyps metachronous
Mean age at presentation 63.7 years
Mean age at presentation 61.0 years
Mean age at presentation 57.1 years
We extracted genomic DNA from peripheral blood of 82 selected patients from the Endoscopy Department of the 12 De Octubre Hospital. We isolated genomic DNA with the automatic Blood Extraction Kit based on magnetic bed technology according to manufacturer protocol (Masswell Promega, Madison, WI USA). We measured DNA concentration using a NanoDrop 1000 spectrophotometer (NanoDrop Technologies Inc., Wilmington, DE, USA) and we diluted the samples to a final concentration of 10 ng/μl.
Primers used for HRM-PCR, identification of the assay conditions
MUTYH HRM and sequencing primer sequences
Amplicon size (base pairs)
MUTYH sequencing primer sequences
Amplicon size (base pairs)
First we designed primers to flank the coding regions of MUTYH exons and analyzed each amplicon in order to ensure that it contained a single melting domain using the Poland program http://www.biophys.uni-duesseldorf.de/local/POLAND/poland.html. We included intronic SNPs, close to the exon boundary, always respecting the condition of amplicons under 300 bp. This was possible as the size of MUTYH exons allowed this design. All primer sequences were analyzed (http://genome.ucsc.edu/cgi-bin/hgPcr) to adjust the likelihood that interferences would not co-amplify with the target sequence melting curves.
In monoallelic mutation carriers, we evaluated by HRM-PCR and sequencing entire MUTYH gene in search of another possible alteration.
This was performed and monitored in a Light Cycler 480 machine (Roche Diagnostics, Penzberg, Germany). HRM-PCR was performed in several rounds, the first one discriminating heteroduplex and homoduplex patterns. First round: we amplified DNA fragments (MUTYH exons 7, 12 and 13) from 5-10 ng genomic DNA. Full reactions contained final concentrations of reagents as follows: 2 mM MgCl2, 0.12 μΜ forward and reverse primers listed in Table 2, 2 × HRM Master (containing ResoLight dye) and DNA. Full HRM-PCR cycling and melting conditions were as follows: 95°C,10 min; 40 cycles of (95°C, 10 s; 60°C fluorescence reading, 10 s; 72°C, 15 s) then melting of (95°C, 1 min; 40°C, 1 min; 60°C, 1 s; 95°C 25 acquisitions per °C). We performed several rounds in each exon, using re-extracted DNA samples and the same concentration of arrangements and conditions. For reproducibility, the analyst repeated the procedures on three different days.
HRM analyses were performed on the latest Software (v.1.5) and the results were blinded to the sequencing data. The melting curves were normalized and temperature shifted, to permit samples to be compared. Significant differences in fluorescence from the horizontal baseline, previously selected, were indicative of mutations. For an evaluation of the mutation detection obtained via HRM-PCR, mutation-containing DNA was amplified using the full HRM-PCR program. In order to remove background fluorescence we subjected raw fluorescence data to normalization and temperature shifting. The probability that the observed melting temperature (Tm) separation of alternative homozygotes was assessed using the nonparametric Mann-Whitney test. We started HRM analyses with sensitivity 0.3 and it was adjusted in the following rounds.
In monoallelic mutation carriers, we evaluated entire MUTYH gene in search of another possible alteration, by HRM-PCR: Full reactions contained final concentrations of reagents as follows: 2 mM MgCl2, 0.12 μΜ forward and reverse primers listed in Table 3, 2 × HRM Master (containing ResoLight dye). Full HRM-PCR touch-down cycling and melting conditions were as follows: 95°C,10 min; 40 cycles of (95°C, 10 s; (65°C-58°C step size 0,5°C and step delay 1 cycle, fluorescence reading), 10 s; 72°C, 15 s) then melting of (95°C, 1 min; 40°C, 1 min; 60°C, 1 s; 95°C 25 acquisitions per °C). The analyst repeated the procedures on three different days.
We sequenced all samples, to evaluate the detection of MUTYH mutations and correlate these with HRM results. Amplifying DNA fragments from 50-100 ng. Reactions contained final concentrations of reagents as follows: 0.8 mM MgCl2, 0.7 μΜ forward and reverse primers listed in Table 2 and Table 3, 1 × Taq polymerase fast start (Roche Diagnostics, Penzberg, Germany) and DNA. PCR cycling and conditions were: 95°C, 10 min; 35 cycles of (95°C, 30 s; 60°C, 30 s; 72°C, 30 s) and 72°C, 10 min. PCR products were purified with ExosapIT (GE Healthcare) followed by sequencing reaction with Big Dye Terminator v3.1 (Applied Biosystems, Foster City, CA) according to the manufacturer's protocol. The sequencing products were purified using AutoSeq G-50 Dye Terminator (GE Healthcare) before running on a 3130 Genetic Analyser (Applied Biosystems, Foster City, CA).
HRM genotyping of MUTYH gene was performed at the 12 De Octubre Hospital for genomics genotyping Core Facility.
The statistical program used for the analysis was SPSS version 15.0. The association between categorical variables was made by χ2 test and Fisher exact test and odds ratio was used to measure the strength of the association. The association between continuous variables was conducted by comparing means using the T test of Student or Mann-Whitney. The significance level was at <or equal to 0.05.
MUTYH germline mutations were found in 15.8 percent, i.e. 13/82 of the patients. Biallelic MUTYH germline mutations were found in 8.5%, i.e. 7/82 which also showed an attenuated polyposis phenotype. Monoallelic MUTYH germline mutations were found in 7.3% i.e. 6/82 of the patients. In monoallelic mutation carriers, we performed HRM-PCR and sequenced entire MUTYH gene in search of another possible alteration: another mutation was detected in two cases (2/8 entire gene studied cases).
The hot spots: Y179C (exon 7) and G396D (exon 13) were found, as well as the five mutations already reported E410GfsX43 (exon 13), R426C (exon 13), R354GfsX40 (exon 12), V232F (exon 9) and V22M (exon 2).
G338H polymorphism (exon 12) was also analyzed in the cohort of 82 subjects and it was found in 23.1%, i.e. 19/82.
MUTYH mutation prevalence for 82 patients with multiple adenomas (≥10), determined via HRM-PCR and via sequencing
Y179C (exon 7)
G396D (exon 13)
E410GfsX43 (exon 13)
R426C (exon 13)
V232F (exon 9)
V22M (exon 2)
R354GfsX40 (exon 12)
G338H (exon 12)
Phenotypic and genotypic features in the 7 patients carriers of biallelic MUTYH germline mutations
Patients with biallelic germline mutations
Number of adenomas (≥10) synchronous or metachronous
Y179C (exon 7) homozygous
Polyps synchronous Age 58
V22M (exon 2) E410GfsX43 (exon 13) double heterozygote
Polyps synchronous Age 42
R426C (exon 13) E410GfsX43 (exon 13) double heterozygote
Yes Age diagnosis Astler-Coller A
R426C (exon 13) R354GfsX40 (exon 12) double heterozygote
Polyps metachronous Age 67
Y179C (exon 7) E410GfsX43 (exon 13) double heterozygote
Yes Age diagnosis Astler-Coller B1
G396D (exon 13) V232F (exon 9) double heterozygote
Polyps synchronous Age 82
G396D (exon 13) homozygous
Polyps synchronous Age 58
Phenotypic and genotypic features in the 6 patients carriers of monoallelic MUTYH germline mutations
Patients with monollelic germline mutations
Number of adenomas (≥ 10) synchronous or metachronous
Y179C (exon 7) heterozygote
Polyps synchronous Age 43
G396D (exon 13) heterozygote
Polyps metachronous Age 42
Yes Age diagnosis Astler-Coller A
R426C (exon 13) heterozygote
Polyps synchronous Age 74
G396D (exon 13) heterozygote (MUTYH and APC genes are mutated) In APC gene L126S heterozygous
Polyps synchronous Age 51
G396D (exon 13) heterozygote
Polyps metachronous Age 70
E410GfsX43 (exon 13) heterozygote
Polyps metachronous Age 39
Phenotypic and genotypic features in the 19 patients carriers of polymorphism G338H (exon 12)
Type of adenomas
In 9 cases no information was available
Patients with multiple (≥ 10) polyps synchronous
Patients with multiple (≥ 10) polyps metachronous
To assess the ability to differentiate between alleles, by high resolution melting technique [10–12], PCR products (first and subsequent rounds) were processed by latest Software (v.1.5) and the results were blinded to the sequencing data [13–15]. First round HRM-PCR (exon 7 with sensitivity of 0.3 and exon 13 with sensitivity of 0.45) discriminated between heteroduplex, wild homoduplex and mutant homoduplex patterns. Several rounds were carried out, as a confirmatory method and to set up the appropriate sensitivity of each exon. For reproducibility, the analyst repeated the procedures on three different days, with equivalent results. We did not have any false calls.
We found MUTYH germline mutations in 15.8 percent, i.e. 13/82 of the patients with multiple adenomas. This percentage is obtained from the analysis of three exons, 7,12 and 13 in the 82 cases and the posterior analysis of entire MUTYH gene in monoallelic mutation carriers. We believe it feasible that this percentage would be slightly increased if we analyze the entire gene in the 82 cases. We gathered information from the most prevalent hot spots at that moment in Spain.
The average age at diagnosis of CRC in studied families was 57 years (ranging from 24 to 86).
In contrast, classical FAP (familial adenomatous polyposis) patients, as is described in the literature [16–18], show a CRC onset 10 years earlier than MAP (mean age at presentation 39 versus 53 respectively).
It appears that disease symptoms in the 7 MAP patients are not as severe as those observed in APC driven FAP. The mutations found along the MUTYH gene were as follows: the hot spots Y179C and G396D; and as well as the five mutations already reported. The highest prevalence of mutations corresponds to the hot spots mentioned above.
In the study of G338H non-pathogenic polymorphism (exon 12) our data indicate no association with attenuated familial adenomatous polyposis (MAP) in this selected group.
By discriminating between distinctive individuals based on their featured high-resolution melting curves, one of the most challenging tasks is the discrimination of amplicons differing by homoduplexes. HRM is a rapid and informative toll, but requires specific primers and refines the sensitivity post-PCR analysis in case of differing homoduplexes. We demonstrate that this tool, HRM, can also be used to detect homozygous mutations in MAP patients. In this way, homozygous mutations show a mutated homoduplex by HRM which is perfectly discriminated against wild type homoduplex and against mutated heteroduplex. (Figures 1, 2 and 3).
A HRM pre-screening assay of exons 7, 12 and 13 could be integrated into the laboratory routine, so that a large number of samples can be screened for identification of samples of interest.
We estimate that by using HRM as a screening method, the number of sequencing reactions requiring MUTYH mutation detection can be reduced by up to 80% thus resulting in substantial time and cost savings. Sequencing is reduced, because once HRM-PCR is optimized for this gene, only abnormal patterns are sequenced. This shows the high resolving power of HRM, compared with direct sequencing. Hence HRM can be used to combat unknown mutation-detection technologies. We refine the capabilities of HRM-PCR and apply it to a gene not yet analyzed by this method.
The combination of real-time PCR and high-resolution melting curve analysis provides an approach to successfully scan exons 7, 12 and 13 of MUTYH gene for these clinically important and frequent mutations.
In conclusion, we describe a screening method HRM, to detect heterozygous and homozygous mutations in the gene encoding MUTYH in selected samples of patients with phenotype of MAP. As clinical decisions will increasingly rely on molecular medicine, the power of identifying germline mutations must be continuously evaluated and improved.
We gratefully acknowledge the assistance of E. Gil and E. Rueda at the 12 De Octubre Hospital Partners for Genetics and Genomics High Throughput Genotyping Facility.
This work was backed by a training grant from Laín Entralgo Agency.
- Gómez-Fernández N, Castellví-Bel S, Fernández-Rozadilla C, Balaguer F, Muñoz J, Madrigal I, Milà M, Graña B, Vega A, Castells A, Carracedo A, Ruiz-Ponte C: Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations. BMC Med Genet. 2009, 10: 57-68. 10.1186/1471-2350-10-57.View ArticlePubMedPubMed CentralGoogle Scholar
- Taylor CF: Mutation scanning using high-resolution melting. Biochem Soc Tran. 2009, 37: 433-7. 10.1042/BST0370433.View ArticleGoogle Scholar
- Tao H, Shinmura K, Suzuki M, Kono S, Mibu R, Tanaka M, Kakeji Y, Maehara Y, Okamura T, Ikejiri K, Futami K, Yasunami Y, Maekawa T, Takenaka K, Ichimiya H, Imaizumi N, Sugimura H: Association between genetic polymorphisms of the base excision repair gene MUTYH and increased colorectal cancer risk in a Japanese population. Cancer Sci. 2008, 99: 355-60. 10.1111/j.1349-7006.2007.00694.x.View ArticlePubMedGoogle Scholar
- Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS: Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Onco. 2009, 24: 3975-80. 10.1200/JCO.2008.21.6853. (2009)View ArticleGoogle Scholar
- Fuster O, Barragán E, Bolufer P, Cervera J, Larráyoz MJ, Jiménez-Velasco A, Martínez-López J, Valencia A, Moscardó F, Sanz MA: Rapid detection of KIT mutations in core-binding factor acute myeloid leukaemia using high-resolution melting analysis. J Mol Diagn. 2009, 5: 458-63. 10.2353/jmoldx.2009.090043.View ArticleGoogle Scholar
- Sampson JR, Jones N: MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol. 2009, 23: 209-18. 10.1016/j.bpg.2009.03.006.View ArticlePubMedGoogle Scholar
- Bouguen G, Manfredi S, Blayau M, Dugast C, Buecher B, Bonneau D, Siproudhis L, David V, Bretagne JF: Colorectal adenomatous polyposis Associated with MYH mutations: genotype and phenotype characteristics. Dis Colon Rectum. 2007, 50: 1612-7. 10.1007/s10350-007-9027-0.View ArticlePubMedGoogle Scholar
- Isidro G, Laranjeira F, Pires A, Leite J, Regateiro F, Castro e Sousa F, Soares J, Castro C, Giria J, Brito MJ, Medeira A, Teixeira R, Morna H, Gaspar I, Marinho C, Jorge R, Brehm A, Ramos JS, Boavida MG: Germline MUTYH (MYH) mutations in Portuguese individuals with multiple colorectal adenomas. Hum Mutat. 2004, 24: 353-10.1002/humu.9282.View ArticlePubMedGoogle Scholar
- Yanaru-Fujisawa R, Matsumoto T, Ushijima Y, Esaki M, Hirahashi M, Gushima M, Yao T, Nakabeppu Y, Iida M: Genomic and functional analyses of MUTYH in Japanese patients with adenomatous polyposis. Clin Genet. 2008, 73: 545-53. 10.1111/j.1399-0004.2008.00998.x.View ArticlePubMedGoogle Scholar
- Wittwer CT: High-resolution DNA melting analysis: advancements and limitations. Hum Mutat. 2009, 30: 857-9. 10.1002/humu.20951.View ArticlePubMedGoogle Scholar
- Whitehall V, Tran K, Umapathy A, Grieu F, Hewitt C, Evans TJ, Ismail T, Li WQ, Collins P, Ravetto P, Leggett B, Salto-Tellez M, Soong R, Fox S, Scott RJ, Dobrovic A, Iacopetta B: A multicenter blinded study to evaluate KRAS mutation testing methodologies in the clinical setting. J Mol Diagn. 2009, 11: 543-52. 10.2353/jmoldx.2009.090057.View ArticlePubMedPubMed CentralGoogle Scholar
- Ma ES, Wong CL, Law FB, Chan WK, Siu D: Detection of KRAS mutations in colorectal cancer by high resolution melting analysis. J Clin Pathol. 2009, 10: 886-91. 10.1136/jcp.2008.063677.View ArticleGoogle Scholar
- Heideman DA, et al: A panel of high resolution melting (HRM) technology-based assays with direct sequencing possibility for effective mutation screening of EGFR and K-ras genes. Cell Oncol. 2009, 31: 329-33.PubMedPubMed CentralGoogle Scholar
- Jiménez Ide J, Esteban Cardeñosa E, Palanca Suela S, González EB, Bolufer Gilabert P: Advantages of the high resolution melting in the detection of BRCA1 or BRCA2 mutation carriers. Clin Biochem. 2009, 42: 1572-6. 10.1016/j.clinbiochem.2009.07.010.View ArticlePubMedGoogle Scholar
- Doi Y, et al: High-resolution melting analysis for a reliable and two-step scanning of mutations in the tyrosine kinasine domain of the chimerical bcr-abl gene. Int J Hematol. 2009, 90: 37-43. 10.1007/s12185-009-0337-y.View ArticlePubMedGoogle Scholar
- Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, Gallinger S: Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev. 2006, 15: 312-4. 10.1158/1055-9965.EPI-05-0793.View ArticlePubMedGoogle Scholar
- Filipe B, Baltazar C, Albuquerque C, Fragoso S, Lage P, Vitoriano I, Mão de Ferro S, Claro I, Rodrigues P, Fidalgo P, Chaves P, Cravo M, Nobre Leitão C: APC or MUTYH mutations account for the majority of clinically well-characterized families with FAP and AFAP phenotype and patients with more than 30 adenomas. Clin Genet. 2009, 76: 242-55. 10.1111/j.1399-0004.2009.01241.x.View ArticlePubMedGoogle Scholar
- Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, La Plant B, French AJ, Laurie JA, Goldberg RM, Thibodeau SN, Witzig TE: Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology. 2006, 131: 729-37. 10.1053/j.gastro.2006.06.005.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://0-www.biomedcentral.com.brum.beds.ac.uk/1471-2407/10/408/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.